Articles On Cann Group (ASX:CAN)

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Research in Australia shows marijuana helps with chronic pain and insomnia The rules around getting prescriptions for medicinal cannabis A quick look at the winners and losers of ASX weed stocks   Sufferers of chronic pain and insomnia ha...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Studies confirm that cannabis relieves pain in cancer patients In addition, cannabis also improves sleep and cognitive function in cancer patients We take a look at the biggest movers in ASX weed stocks over the past week   It’s now offic...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The 420 Day is unofficially the World Marijuana Day, and we look at the possible origins of this day Cannabis stocks have been falling, but there’s still a lot of promise We take a look at the cannabis stocks on the ASX over the past week...

The number of Aussies using legal instead of illicit medical cannabis is rising The main reason for using prescribed medicinal cannabis was chronic pain, says Sydney Uni survey We take a look at what made the news in ASX weed stocks this p...

Chemist Warehouse joins WNX JV to develop new cannabis products Neurotech launches new clinical program for its NTI164 drug in Rett Syndrome InhaleRx nabs approval for Phase 1 IRX211 clinical trial for Complex Regional Pain Syndrome   Wel...

The Swiss government has moved quickly to shore up its uniqueness as a centre of commerce – albeit one where the banks eat each other – and hurriedly green-lit (no pun) plans to legalise the sale and consumption of cannabis in Zurich, Switz...

ASX cannabis stocks provide a valuable service to the many thousands of Australians who benefit from the legal, medicinal benefits of their product. All told, the cannabis shares have grown, cured, and prepared medicinal marijuana products...

Alcidion increased sales significantly in the first half Cogstate sounds warning on outlook Probiotic had a super half   Most biotech firms on the ASX are clinical stage companies, meaning they are still trying to prove that their drugs a...

Twitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on top with CannaCare Health arbitration awarded in their favour Avecho expands CBD soft-gel capsule trials with the Lambert Initiative   Twi...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

US States who allow recreational cannabis see less codeine demand WA GP wants Snoop Dogg to drop into parliament to chat cannabis reform Neurotech nabs pre-submission meeting with US FDA for CBD drug NTI164   A Cornell University study ha...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Germany: Next target for cannabis producers, huge market and could be live in 12 months Other Euro states about to legislate on industry in next few years Stockhead reached out to Little Green Pharma’s founder and CEO, Fleta Solomon   Fol...

Cann Group (CAN) appoints Peter Koetsier as its new CEO following an extensive search process Mr Koetsier will replace Peter Crock, who announced that he would be stepping down as CEO of the company last October The incoming CEO has...

Less than two months after announcing that Peter Crook would be stepping down as top boss, medicinal cannabis company Cann Group (ASX: CAN) has appointed Peter Koetsier as its new CEO from 16 January. The incoming executive held senior pos...

The ASX will open marginally lower on Tuesday Overnight, Wall Street was mixed but turned negative after comments from US Fed policymakers Oil prices rose another 1pc   Aussie shares will open marginally lower this morning, and at 8am AED...

Penington Institute says pot-related law enforcement costs us $1.7 billion a year   Local cannabis is missing out on international and domestic market opportunities Aussie medicinal cannabis revenue was around $230 million in 2021   Decri...

ASX Health sector has ended its upward trend falling 0.7% in the past five days in line with broader markets As the end of 2022 approaches several ASX health stocks announce capital raising results to secure funding Healius announces sal...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Two more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Victorian medical cannabis facility is safe from flooding in the state, so far Cann looks to commercialise its Satipharm CBD capsules for over-...

Germany looks to legalise recreational cannabis and US and Canadian companies are paying attention  Neurotech reports success with its cannabis-based drug for paediatric autism symptoms  ECS Botanics has sold its Tasmanian business and a...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.3% to 6,799.7 points. Four ASX shares that have failed to follow the market higher today are...

Peter Crock resigns as CEO of Cann Group (CAN) but will remain in the position until a new CEO has been appointedSince joining Cann in May 2016, Mr Crock led the company through its IPO and helped raise $13.5 million to support it A search...

The man who led medicinal cannabis company Cann Group (ASX: CAN) through its 2017 initial public offering (IPO) is set to step down after six years in the role, leaving behind a legacy of three production sites including a flagship $115 mil...

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

ASX cannabis shares have leapt back onto investor radars and are likely to grab more media headlines in the weeks ahead. While all three are deep in the red today amid wider selling action that sees the All Ordinaries Index (ASX: XAO) down...

ShareCafeASX moves lower amidst fears of another Fed rate hike: Aus shares 0.6% down at noon by Peter Milios   At noon, S&P/ASX 200 is 0.61 per cent or 41.90 points lower at 6775.60, following a tumultuous day in the US markets, as the...

ShareCafeStocks of the Hour: TBN, KGD                    Cannabis stocks were the highlight overnight as President Joe Biden pardoned all prior federal offences of simple marijuana possession. This has flowed through to medicinal cann...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index   It turns out that the lazy stoner stereotype is actually a myth,...

Researchers say data shows transition from illicit to legal use of cannabis Medicinal users are at 37%, compared to 2.5% in 2018 Regulations, quality control and costs still barriers for legal week users   New research from the University...

ASX cannabis shares have been mixed performers on the market in the year to date, but are there better days ahead? Cannabis shares on the ASX include Cronos Australia Ltd (ASX: CAU), Incannex Healthcare Ltd (ASX: IHL), Emyria Ltd (ASX: E...

Ice-T is opening a cannabis dispensary in New Jersey this year Snoop Dogg’s venture capital firm led a seed funding round for TSUMo Snacks Incannex ramps up development and manufacturing of IHL-216A drug New Jersey has given Ice-T the gre...

Mysterious pink glow over Mildura Thailand businesses go nuts for CBD desserts and bubble tea ECS nabs $2m commercial loan facility to invest in new capacity ICYMI a mysterious pink glow above Mildura sent residents into a bit of a frenzy...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

ECS is selling its medicinal cannabis farm in Tasmania Crypto ATMs are now a thing in weed dispensaries in the US Zelira Therapeutics nabs regulatory approval in Germany for insomnia medication Ever fancied your own cannabis farm? Well, t...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Retail and independent cannabis lounges could be opening soon in Vegas Cann Group gets good manufacturing practice (GMP) licence for its Mildura facility Bod plans to launch a low dose CBD schedule 3 product into the Australian market  ...

The ASX 200 closes lower Small caps lose circa 18% in June Control Bionics jumps 60%   It’s been an exhausting June for Aussie small caps. Down again on Thursday as the energy sector wilts, the S&P Emerging Companies (XEC) has lost 18...

Cann Group (CAN) receives a good manufacturing practice (GMP) licence for its Mildura facility in Victoria from the Therapeutic Goods Administration (TGA) This licence allows Cann to produce active pharmaceutical ingredients and hard capsu...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another decline. At the time of writing, the benchmark index is down 0.9% to 6,639.3 points. Four ASX shares that are not letting that hold them back are list...

The Cann Group Ltd (ASX: CAN) share price is rocketing on Thursday. This comes after the cannabis company announced a positive update regarding its Mildura facility. At the time of writing, Cann shares are fetching at 27.5 cents, up 19.57%...

Cann Group’s Mildura facility has been granted GMP licence Paradigm receives patent application acceptance by IP Australia Starpharma to relaunch VIRALZEE with LloydsPharmacy in the UK Cannabis company Cann Group (ASX:CAN) rose 17% this m...

A Thai university says adding cannabis to chicken feed has positive results on meat and egg quality Aussie cannabis campaigner now a Member of the Order of Australia MGC Pharma’s CBD treatment proves effective against brain tumors   Chian...

Boston Beer Co launches cannabis iced tea in Canada University of Sydney says using CBD and driving is no worries Emyria reports positive Phase 1 study results for ultra-pure CBD capsule The Boston Beer Co is launching a line of cannabis-...

Fresh from receiving permission in March to start cultivating medicinal cannabis at its northwest Victorian facility in Mildura, Cann Group (ASX: CAN) has announced it has commenced harvesting the first crop at its new flagship site. The M...